Hydrogen-1 MR spectroscopy (MRS) studies demonstrate metabolic differences between patients who have Alzheimer's disease (AD) and cognitive normal age-matched controls. Clinical MRS also shows regional variations in metabolites between patients who have AD and those who have other dementias. Single-voxel and volumetric standard MRS techniques and automated data processing software are available for clinical MR scanners. Improvements in specificity and sensitivity of AD diagnosis, using MRS techniques as an adjunct to clinical imaging, are under evaluation. Multiparametric data analyses show, however, that metabolite changes correlate with in-vitro, postmortem, and metabolic changes and to changes in or predictions of cognitive scores.